Shares of Gilead Sciences Inc. (GILD) are rallying after the company announced more trials for Coronavirus treatment. The company, on Feb. 26, has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus).
The company noted that the randomized, open-label, multicenter studies will enroll about 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com